Advanced search
1 file | 26.19 MB Add to list

Case report : dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma : a proteome analysis

Manon Blauwblomme (UGent) , Philippe Gevaert (UGent) , Sharon Van Nevel (UGent) , Sebastian Riemann (UGent) , Elke Vandewalle (UGent) , Gabriële Holtappels (UGent) , Natalie De Ruyck (UGent) , Lara Derycke (UGent) , Anne-Sophie Eeckels (UGent) , Stijn Vanhee (UGent) , et al.
Author
Organization
Project
Abstract
Context Recent insights into type 2 inflammation have led to the development of monoclonal antibody therapies for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Despite add-on therapy with a monoclonal antibody, some individuals remain uncontrolled in terms of upper and/or lower airway symptoms, prompting an exploration of the efficacy of combining biological therapies and their impact on inflammatory pathways.Objectives In this article, we present a distinctive case of a patient with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, who experienced substantial clinical and local inflammatory improvements through dual monoclonal antibody therapy.Methods We provide a detailed case description and analysis of the patient's nasal tissue and secretions to gain insights into the local nasal inflammation under this unique therapeutic approach.Results The addition of an anti-IL-4R alpha antibody led to an improvement in upper airway symptoms and a reduction in both eosinophilic and neutrophilic inflammation, despite prior anti-IL-5 therapy. These effects were consistently observed in both polyp tissue and nasal secretions.Conclusion Our patient, with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, experienced substantial improvement with dual monoclonal antibody therapy, without major complications or side effects.
Keywords
chronic rhinosinusitis with nasal polyps (CRSwNP), severe eosinophilic asthma, mepolizumab, dupilumab, dual monoclonal antibody therapy, proteomic analysis

Downloads

  • publisher version.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 26.19 MB

Citation

Please use this url to cite or link to this publication:

MLA
Blauwblomme, Manon, et al. “Case Report : Dual Monoclonal Antibody Therapy in Chronic Rhinosinusitis with Nasal Polyps and Severe Eosinophilic Asthma : A Proteome Analysis.” FRONTIERS IN ALLERGY, vol. 5, 2024, doi:10.3389/falgy.2024.1484931.
APA
Blauwblomme, M., Gevaert, P., Van Nevel, S., Riemann, S., Vandewalle, E., Holtappels, G., … Van Zele, T. (2024). Case report : dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma : a proteome analysis. FRONTIERS IN ALLERGY, 5. https://doi.org/10.3389/falgy.2024.1484931
Chicago author-date
Blauwblomme, Manon, Philippe Gevaert, Sharon Van Nevel, Sebastian Riemann, Elke Vandewalle, Gabriële Holtappels, Natalie De Ruyck, et al. 2024. “Case Report : Dual Monoclonal Antibody Therapy in Chronic Rhinosinusitis with Nasal Polyps and Severe Eosinophilic Asthma : A Proteome Analysis.” FRONTIERS IN ALLERGY 5. https://doi.org/10.3389/falgy.2024.1484931.
Chicago author-date (all authors)
Blauwblomme, Manon, Philippe Gevaert, Sharon Van Nevel, Sebastian Riemann, Elke Vandewalle, Gabriële Holtappels, Natalie De Ruyck, Lara Derycke, Anne-Sophie Eeckels, Stijn Vanhee, Bart Lambrecht, Guy Brusselle, and Thibaut Van Zele. 2024. “Case Report : Dual Monoclonal Antibody Therapy in Chronic Rhinosinusitis with Nasal Polyps and Severe Eosinophilic Asthma : A Proteome Analysis.” FRONTIERS IN ALLERGY 5. doi:10.3389/falgy.2024.1484931.
Vancouver
1.
Blauwblomme M, Gevaert P, Van Nevel S, Riemann S, Vandewalle E, Holtappels G, et al. Case report : dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma : a proteome analysis. FRONTIERS IN ALLERGY. 2024;5.
IEEE
[1]
M. Blauwblomme et al., “Case report : dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma : a proteome analysis,” FRONTIERS IN ALLERGY, vol. 5, 2024.
@article{01JCN4GW9GA2D5DC4XV9JCGAZH,
  abstract     = {{Context Recent insights into type 2 inflammation have led to the development of monoclonal antibody therapies for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Despite add-on therapy with a monoclonal antibody, some individuals remain uncontrolled in terms of upper and/or lower airway symptoms, prompting an exploration of the efficacy of combining biological therapies and their impact on inflammatory pathways.Objectives In this article, we present a distinctive case of a patient with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, who experienced substantial clinical and local inflammatory improvements through dual monoclonal antibody therapy.Methods We provide a detailed case description and analysis of the patient's nasal tissue and secretions to gain insights into the local nasal inflammation under this unique therapeutic approach.Results The addition of an anti-IL-4R alpha antibody led to an improvement in upper airway symptoms and a reduction in both eosinophilic and neutrophilic inflammation, despite prior anti-IL-5 therapy. These effects were consistently observed in both polyp tissue and nasal secretions.Conclusion Our patient, with CRSwNP, severe eosinophilic asthma, and uncontrolled upper airway symptoms, experienced substantial improvement with dual monoclonal antibody therapy, without major complications or side effects.}},
  articleno    = {{1484931}},
  author       = {{Blauwblomme, Manon and Gevaert, Philippe and Van Nevel, Sharon and Riemann, Sebastian and Vandewalle, Elke and Holtappels, Gabriële and De Ruyck, Natalie and Derycke, Lara and Eeckels, Anne-Sophie and Vanhee, Stijn and Lambrecht, Bart and Brusselle, Guy and Van Zele, Thibaut}},
  issn         = {{2673-6101}},
  journal      = {{FRONTIERS IN ALLERGY}},
  keywords     = {{chronic rhinosinusitis with nasal polyps (CRSwNP),severe eosinophilic asthma,mepolizumab,dupilumab,dual monoclonal antibody therapy,proteomic analysis}},
  language     = {{eng}},
  pages        = {{7}},
  title        = {{Case report : dual monoclonal antibody therapy in chronic rhinosinusitis with nasal polyps and severe eosinophilic asthma : a proteome analysis}},
  url          = {{http://doi.org/10.3389/falgy.2024.1484931}},
  volume       = {{5}},
  year         = {{2024}},
}

Altmetric
View in Altmetric